Vanda Pharmaceuticals Inc (VNDA)

NASDAQ
17.96
+0.10(+0.56%)
  • Volume:
    139,911
  • Bid/Ask:
    17.93/17.99
  • Day's Range:
    17.54 - 18.10

VNDA Overview

Prev. Close
17.86
Day's Range
17.54 - 18.1
Revenue
252.84M
Open
17.53
52 wk Range
9 - 20.51
EPS
0.57
Volume
139,911
Market Cap
997.93M
Dividend (Yield)
N/A (N/A)
Average Vol. (3m)
558,057
P/E Ratio
31.54
Beta
0.47
1-Year Change
60.04%
Shares Outstanding
55,564,214
Next Earnings Date
Aug 04, 2021
What is your sentiment on Vanda Pharmaceuticals Inc?
or
Vote to see community's results!

Vanda Pharmaceuticals Inc News

Vanda Pharmaceuticals Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellBuyBuyStrong BuyStrong Buy
Technical IndicatorsStrong SellNeutralStrong BuyStrong BuyStrong Buy
SummaryStrong SellNeutralStrong BuyStrong BuyStrong Buy

Vanda Pharmaceuticals Inc Company Profile

Vanda Pharmaceuticals Inc Company Profile

Sector
Services
Employees
292

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome. It offers Fanapt for the treatment of schizophrenia. Fanapt has potential utility in various other disorders. Tradipitant is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. AQW051 is indicated for the treatment of central nervous system disorders.

Read More
  • 🚀🚀🚀
    1
    • Why down??
      1
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.